WO2010121455A1 - 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 - Google Patents
使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 Download PDFInfo
- Publication number
- WO2010121455A1 WO2010121455A1 PCT/CN2009/073382 CN2009073382W WO2010121455A1 WO 2010121455 A1 WO2010121455 A1 WO 2010121455A1 CN 2009073382 W CN2009073382 W CN 2009073382W WO 2010121455 A1 WO2010121455 A1 WO 2010121455A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- block
- tumor
- polymeric micelle
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
Definitions
- composition for treating tumors using polymeric micelles containing anti-tumor drugs comprising:
- the present disclosure relates to pharmaceutical compositions for treating tumors using polymeric micelles that encapsulate the anti-tumor drug.
- the polymeric micelle comprises a block copolymer comprising at least one hydrophilic block, at least one hydrophobic block and At least one zwitterions.
- the antitumor drug is, for example, hydrophobic.
- the present disclosure also relates to methods of enhancing the solubility of anti-tumor drugs, methods of increasing the blood circulation time of anti-tumor drugs, and methods of delivering anti-tumor drugs to one or more solid tumors. Background technique
- CPT camptothecin
- an inhibitor of DNA topoisomerase I has been shown to be a therapeutic candidate for the treatment of tumors.
- CPT has a terminal ring which is converted between a lactone form in an acidic medium (pH ⁇ 5) and a ring-opened carboxylate form in an alkaline medium (pH > 8), but only internally
- the ester form CPT is pharmaceutically active.
- this active form is hydrophobic and therefore has difficulty in delivery in a physiological environment.
- CPT its biological analogues, such as 7-ethyl-10-hydroxycamptothecin (SN38, ie
- CPT11 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT11) and some other antitumor drugs in physiological environment It also has poor solubility and similar active form-inactive form conversion problems. Because these drugs may be highly toxic and rapidly metabolized, it is desirable to introduce and deliver therapeutic levels of the drug to solid tumors while reducing their toxicity.
- the present disclosure provides a pharmaceutical composition for treating a tumor using a polymeric micelle of a coated anti-tumor drug, wherein the polymeric micelle comprises a block copolymer, the block copolymer comprising a Or a plurality of hydrophilic blocks, one or more hydrophobic blocks, and one or more zwitterions.
- the hydrophobic block may comprise at least one entity selected from the group consisting of polycaprolactone (PCL), polyvalerolactone (PVL), and poly(lactide). ⁇ (poly(lactide-co-glycolide), PLGA), polylactic acid (PLA), polybutyrolactone (PBL), polyglycolide and polypropionide
- the hydrophilic block may comprise at least one entity selected from, for example, polyethylene glycol (PEG), hyaluronic acid (HA), and poly-gamma-glutamic acid (poly -y-glutamine acid, ⁇ -PGA).
- the zwitterion may comprise at least one entity selected from the group consisting of phosphorylcholine (PC), and betaine betaine.
- the antitumor drug encapsulated in the polymeric micelle may be a single drug or a combination of different drugs.
- the present disclosure also relates to methods of enhancing the solubility of an anti-tumor drug, methods of increasing the blood circulation time of the drug, and methods of delivering the drug to one or more solid tumors. These methods use the polymeric micelles described above to encapsulate at least one anti-tumor drug to increase the solubility of the drug, blood circulation time, and/or deliver the drug to one or more solid tumors.
- Figure 1 shows the release profile of CPT (or SN38) with incubation time for various compositions using a dialysis bag.
- Figure 2 shows the proportion of lactone form CPT (or SN38) remaining with incubation time for each composition using direct dilution.
- Figure 3 shows the quantitative distribution of lactone form CPT in plasma after injection in an in vivo kinetic assay.
- Figure 4 shows the quantitative distribution of lactone form SN38 in plasma after injection in an in vivo kinetic assay.
- Figure 5 shows the size of HT29 tumors after treatment with CCP201 and free CPT11.
- Figure 6 shows the size of HT29 tumors after treatment with SCP201 and free CPT11.
- Figure 7 shows the size of Colo205 tumors after treatment with SCP201 and free CPT11.
- the present disclosure relates to a pharmaceutical composition for treating tumors using polymeric micelles that contain anti-tumor drugs.
- the polymeric micelles comprise a block copolymer comprising at least one hydrophilic block, at least one hydrophobic block, and at least one zwitterion.
- the block copolymer can be, for example, amphiphilic.
- the hydrophobic block has a molecular weight of, for example, from about 500 to about 30,000 Daltons.
- the hydrophobic block may comprise, for example, at least one entity selected from, for example, polycaprolactone (PCL), polyvalerolactone (PVL), poly(lactide co-glycolide) (PLGA), Polylactic acid (PLA), polybutyrolactone (PBL), polyglycolide and polypropion lactone (PPL).
- the hydrophilic block has a molecular weight of, for example, from about 500 to about 30,000 Daltons.
- the hydrophilic block may comprise, for example, at least one entity selected from the group consisting of polyethylene glycol (PEG), hyaluronic acid (HA), and poly-gamma-glutamic acid-PGA.
- the zwitterion may comprise, for example, at least one entity selected from the group consisting of lysine (PC), sulfobetaine (NS) and an amino acid.
- PEG-PCL-PC has the following structure:
- R is a hydrogen atom, an alkyl group, a benzyl group or an acyl group, and the alkyl group, benzyl group or acyl group may be Is unsubstituted or substituted by a functional group, and the hydrogen atom, alkyl group, benzyl group or acyl group may be protected; m and n may be the same or different, each of which is an integer; preferably, m and n are each 1 An integer of 200, more preferably, m and n are each an integer of from 10 to 100, most preferably, m is an integer of from 30 to 85, and n is an integer of from 10 to 80.
- the block copolymers disclosed herein can be prepared by the method disclosed in U.S. Patent Application Publication No. 2007/0104654.
- the block copolymer disclosed in the present application exceeds the critical micelle concentration (critical micelle
- CMC Concentration, is the ability to form polymeric micelles in an aqueous medium in which the hydrophobic portion is embedded in the core.
- the polymeric micelles may, for example, have a diameter of from about 20 to about 10,000 nm. Due to the chain flexibility of hydrophilic blocks and the presence of zwitterions, the polymeric micelles are essentially non-immunogenic.
- the hydrophobic block can be decomposed by enzymatic or hydrolysis.
- the polymeric micelles are biodegradable and/or biocompatible. Therefore, after the hydrophobic block is decomposed, the remaining harmless substances such as hydrophilic blocks and zwitterions are soluble in the blood and then removed from the renal system.
- the antitumor drug encapsulated in the polymeric micelles can be a single drug or a combination of different drugs.
- the polymeric micelles disclosed herein can be used as an effective pharmaceutical carrier and are capable of absorbing at least one hydrophobic drug into its hydrophobic core to form a pharmaceutical composition.
- the present disclosure also relates to methods of enhancing the solubility of an anti-tumor drug, methods of increasing the blood circulation time of the drug, and methods of delivering the drug to one or more solid tumors. These methods use the polymeric micelles disclosed herein to encapsulate at least one anti-tumor drug to increase the solubility, effectiveness or potency of the drug, and to deliver the drug to one or more solid tumors.
- the present disclosure relates to a method of delivering an anti-tumor drug to a solid tumor, the method comprising encapsulating the anti-tumor drug in a polymeric micelle disclosed herein to form an encapsulation complex
- the gingival complex is then delivered to the human body by known drug delivery methods, such as by oral administration, transdermal administration, injection or inhalation.
- the polymeric micelles of the at least one anti-tumor drug disclosed in the present application can be prepared, for example, by the following method.
- a certain amount of the antitumor drug and the block copolymer were stirred and dissolved in 1 ml of dimercaptosulfoxide (DMSO).
- DMSO dimercaptosulfoxide
- 1 ml of a 10% sugar solution was added, and then the freeze-dried solid was dissolved to form a suspension.
- the suspension was further filtered through a 0.45 ⁇ m filter to remove unencapsulated drug crystals, and then polymerized micelles containing at least one antitumor drug were obtained.
- Table 1 shows the selection of various antitumor drugs (CPT or SN38), block copolymers and their amounts in each formulation.
- PEG, PCL, PVL, and PC represent polyethylene glycol, polycaprolactone, polyvalerolactone, and leucoylcholine, respectively, and the attached numbers indicate approximate molecular weights of PEG, PCL, and PVL.
- PEG 5QQQ PCL 19QQ PC means that the block copolymer comprises PEG having a molecular weight of about 5000 Daltons, which is linked to PCL having a molecular weight of about 1900 Daltons, which is further attached to the PC.
- composition code is arbitrarily given to represent different compositions.
- the CC201, CC301, CC701, CV201 and SC201 compositions did not contain any zwitterions and were therefore used for comparison purposes.
- the particle size distribution can be obtained, for example, by a laser particle size analyzer (Coulter N4 plus), and the amount of CPT or SN38 contained in each preparation can be determined by HPLC.
- R S ., RI. and E.E. in Table 1 represent the particle size, polydispersity index and encapsulation efficiency, respectively. These parameters can be measured and/or calculated according to techniques known in the art.
- Example 1 Release test using a dialysis bag
- a 5 (L solution) of the pharmaceutical composition prepared according to the method described above was added to a dialysis bag having a molecular weight cutoff of about 3,500 Daltons, followed by 50 ml of phosphate buffered saline at 37 C. Dialysis was performed (PBS) (pH 7.4). After 0.5, 1, 1.5, 2, 4, and 8 hours of dialysis, 25 ( ⁇ L out-of-bag buffers, respectively, and then 750 ⁇ each were taken out. ⁇ sterol (solution in 0.6 ⁇ HCl) was mixed. The amount of each drug released from the polymeric micelles and then dialyzed into the extra-buffer buffer was determined by HPLC. Use 5 ( ⁇ L of CPT-containing DMSO solution (CPT) -DMSO) For comparison.
- CPT CPT-containing DMSO solution
- Figure 1 shows the release profile of CPT (or SN38) with incubation time for various compositions using a dialysis bag.
- Table 2 shows the raw data.
- A% indicates the percentage of CPN/SN38 released.
- a 15 ( ⁇ L solution of the pharmaceutical composition of the present disclosure prepared according to the method described above was mixed with 135 (L PBS (pH 7.4), and then incubated at 37 ° C. During incubation 0.5, 1, 2, 4 and After 8 hours, 1 (L incubation solution) was separately taken, and then each was mixed with 99 (L). The amount of lactone form CPT or SN38 in the mixture was determined by HPLC. 15 ( ⁇ L of DMSO solution containing CPT (CPT- DMSO) served as a control.
- Figure 2 shows the ratio of lactone form CPT (or SN38) remaining with incubation time for each composition using direct dilution.
- Table 3 shows the raw data.
- A% indicates the percentage of remaining lactone forms CPT and SN38
- CPT at a dose of 1 mg/kg in DMSO, CC201, CCP201 and CV201 was introduced into SD mice by intravenous injection, respectively.
- the concentration of the lactone form of CPT in the blood over time is then determined by HPLC.
- Figure 3 shows the quantitative distribution of lactone form CPT in plasma after injection in an in vivo kinetic test.
- Table 4 shows the raw data.
- Table 5 shows the kinetic data.
- CL mL/hr/kg and Vss (mL/kg) represent the half-life, area under the curve to infinity, clearance and steady-state volume, and their units, respectively.
- n represents the number of samples.
- CCP201 provides the best protection against lactone form of CPT in the blood because T 1/2 (hr) and the plasma lactone form of CPT are related to CCP201.
- the T 1/2 (hr) and the plasma lactone form of CPT About 4 times and 9.5 times, and a zwitterionic polymeric micelle such as CCP201 is more effective in maintaining CPT in the form of a lactone in the blood compared to a zwitterion-free polymeric micelle.
- Table 5 demonstrates that an exemplary embodiment of the present invention is capable of substantially improving the stability of the lactone form of CPT in the presence of HSA and reducing the amount of CPT convertible to the carboxylate form in the presence of HSA.
- Example 4 In vivo kinetics test of SN38
- SN38 at a dose of 4 mg/kg in DMSO, SC201 and SCP201 was introduced into SD mice by intravenous injection, respectively.
- the concentration of the lactone form SN38 in the blood is then determined by HPLC.
- Figure 4 shows the quantitative distribution of lactone form SN38 in plasma after injection in an in vivo kinetic assay.
- Table 6 shows the raw data.
- Table 7 shows the kinetic data.
- CL mL/hr/kg and Vss (mL/kg) represent the half-life, the area under the infinite curve, the clearance rate and the steady-state volume of distribution, and their units, respectively.
- n represents the number of samples.
- Figure 5 shows the size of HT29 tumors after treatment with CCP201 and free CPT11.
- Table 8 shows the raw data and Table 9 shows the summarized data.
- the results indicate that, in general, CCP201 is able to provide higher drug efficacy or potency than free CPT11. Specifically, the tumor inhibition rate of the 18 mg/kg CCP201 dose exceeded 60%, which was significantly higher than the tumor inhibition rate of free CPT11.
- aTIR (1-V treatment group / V control group) * 100
- Figure 6 shows the size of HT29 tumors after treatment with SCP201 and free CPT11.
- Table 10 shows the raw data and Table 11 shows the summarized data.
- aTIR (1-V treatment group / V control group) * 100
- Figure 7 shows the size of Colo205 tumors after treatment with SCP201 and free CPT11.
- the table shows the raw data
- Table 13 shows the summarized data.
- aTIR (1-V treatment group / V control group) * 100
- Table 12 and Table 13 show that, in general, SCP201 is able to provide higher drug efficacy than free CPT11. Specifically, Tables 11 and 13 both show that when 20 mg/kg of SCP201 is used, the tumor inhibition rate against HT29 and Colo205 can be higher than 90%.
- Example 7 In vivo drug efficacy test of SCP201 using MTT assay
- Dulbecco's Modified Eagle Media Dulbecco's Modified Eagle Media
- P/S high glucose
- Table 14 shows the selection of cancer cell lines and CPT11, SN38, respectively, and SCP201 half maximal inhibitory concentration of each tumor cell line (IC 50). The difference in drug activity between CPT11 and SN38 is consistent with the data disclosed in the publication. Table 14 shows that there is no reduction in the in vitro pharmaceutical activity of the pharmaceutical composition comprising SN38 disclosed herein.
- Ovarian cancer OVCAR-3 16.75 ⁇ 1.43 22.73 ⁇ 2.14 28.10 ⁇ 1.69
- lN.D indicates that the human lung cancer cell lines (A549 and AS2) not used in the present application were provided by Prof. Wu-Chou Su (National Cheng Kung University Hospital College of Medicine, Taiwan). Human colorectal cancer (Colo 205 and HT29) was provided by Dr. Ming-Jium Shieh (National Taiwan University College of Medicine and College of Engineering, Taiwan). Human liver cancer cell line SK-HEP-1 was obtained from the American Type Culture Collection (ATCC, Rockville, MD). All remaining cell lines tested in this application were obtained from the Bioresource Collection and Research Center (BCRC, Food Industry Research and Development Institute, Hsinchu, Taiwan).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09843559.7A EP2422816B1 (en) | 2009-04-21 | 2009-08-20 | A drug composition for treating tumor with polymeric micelle encapsulating antineoplastic |
US13/265,802 US8420119B2 (en) | 2009-04-21 | 2009-08-20 | Drug composition for treating tumor with polymeric micelle encapsulating anti-neoplastic |
CA2759060A CA2759060C (en) | 2009-04-21 | 2009-08-20 | A drug composition for treating tumor with polymeric micelle encapsulating anti-neoplastic |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910132138.6A CN101869712B (zh) | 2009-04-21 | 2009-04-21 | 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 |
CN200910132138.6 | 2009-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010121455A1 true WO2010121455A1 (zh) | 2010-10-28 |
Family
ID=42994917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/073382 WO2010121455A1 (zh) | 2009-04-21 | 2009-08-20 | 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8420119B2 (zh) |
EP (1) | EP2422816B1 (zh) |
CN (1) | CN101869712B (zh) |
CA (1) | CA2759060C (zh) |
WO (1) | WO2010121455A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
TWI619496B (zh) | 2011-11-03 | 2018-04-01 | 台灣微脂體股份有限公司 | 疏水性喜樹鹼衍生物之醫藥組合物 |
CN103478145A (zh) * | 2013-09-26 | 2014-01-01 | 卞佳林 | 一种多杀菌素和阿维菌素复合聚合物胶束杀虫剂 |
CN103990135B (zh) * | 2014-05-13 | 2017-02-01 | 广东众生药业股份有限公司 | 两嵌段聚合物负载紫杉烷类药物的胶束及其制备方法和应用 |
GB2542092B (en) * | 2014-07-15 | 2019-05-29 | Teng Xin | Polyethylene glycol methyl ether-polylactide-lysine micellar compositions comprising docetaxel |
WO2016131006A1 (en) * | 2015-02-13 | 2016-08-18 | Orient Pharma Inc. | Compositions and methods of tumor treatment utilizing nanoparticles |
HUE053929T2 (hu) * | 2017-06-22 | 2021-07-28 | Snbioscience Inc | Dupla maghéjszerkezettel rendelkezõ, oldhatatlan kamptotecin-vegyületet tartalmazó részecske és gyógyszerkészítmény és módszer ugyanennek az elõállítására |
CN110478332A (zh) * | 2019-09-12 | 2019-11-22 | 青岛科技大学 | 一种新型聚乙二醇-聚γ丁内酯两嵌段共聚物纳米载药微球的制备方法 |
CN115433349A (zh) * | 2021-06-03 | 2022-12-06 | 中国科学技术大学 | 聚乳酸两性离子化合物、合成方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1531566A (zh) * | 2001-07-14 | 2004-09-22 | ������������ʽ���� | 作为药物载体的带正电的两亲嵌段共聚物及其与带负电的药物的络合物 |
US20070104654A1 (en) | 2005-11-08 | 2007-05-10 | Industrial Technology Research Institute | Amphiphilic block copolymers and nano particles comprising the same |
CN100998870A (zh) * | 2006-11-27 | 2007-07-18 | 涂家生 | 一种稳定的聚合物胶束载药系统 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030059465A1 (en) * | 1998-05-11 | 2003-03-27 | Unger Evan C. | Stabilized nanoparticle formulations of camptotheca derivatives |
TWI246524B (en) * | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US20050220880A1 (en) | 2002-03-07 | 2005-10-06 | Lewis Andrew L | Drug carriers comprising amphiphilic block copolymers |
US20070258889A1 (en) * | 2005-11-09 | 2007-11-08 | Montana State University | Novel nanoparticles and use thereof |
ES2357354T3 (es) * | 2007-04-30 | 2011-04-25 | Intezyne Technologies Inc. | Micelas híbridas de copolímero en bloque con estereoquímica mixta para encapsulación de agentes hidrófobos. |
-
2009
- 2009-04-21 CN CN200910132138.6A patent/CN101869712B/zh active Active
- 2009-08-20 WO PCT/CN2009/073382 patent/WO2010121455A1/zh active Application Filing
- 2009-08-20 US US13/265,802 patent/US8420119B2/en active Active
- 2009-08-20 CA CA2759060A patent/CA2759060C/en active Active
- 2009-08-20 EP EP09843559.7A patent/EP2422816B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1531566A (zh) * | 2001-07-14 | 2004-09-22 | ������������ʽ���� | 作为药物载体的带正电的两亲嵌段共聚物及其与带负电的药物的络合物 |
US20070104654A1 (en) | 2005-11-08 | 2007-05-10 | Industrial Technology Research Institute | Amphiphilic block copolymers and nano particles comprising the same |
US20080166382A1 (en) * | 2005-11-08 | 2008-07-10 | Industrial Technology Research Institute | Amphiphilic block copolymers and nanoparticles comprising the same |
CN100998870A (zh) * | 2006-11-27 | 2007-07-18 | 涂家生 | 一种稳定的聚合物胶束载药系统 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2422816A4 |
Also Published As
Publication number | Publication date |
---|---|
EP2422816A1 (en) | 2012-02-29 |
CN101869712B (zh) | 2016-01-20 |
CA2759060C (en) | 2013-12-24 |
CA2759060A1 (en) | 2010-10-28 |
US8420119B2 (en) | 2013-04-16 |
EP2422816A4 (en) | 2013-12-18 |
US20120100220A1 (en) | 2012-04-26 |
CN101869712A (zh) | 2010-10-27 |
EP2422816B1 (en) | 2015-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010121455A1 (zh) | 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 | |
Zhao et al. | Polyphosphoesters in drug and gene delivery | |
JP6363320B2 (ja) | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 | |
EP2515946B1 (en) | Nanoconjugates and nanoconjugate formulations | |
Chen et al. | KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy | |
US11857634B2 (en) | Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids | |
JP5780775B2 (ja) | プロスタグランジンi2誘導体を含有するナノ粒子 | |
CN102600063A (zh) | 一种高载药量姜黄素胶束的制备方法 | |
CN102099016A (zh) | 载药的聚合物纳米微粒及其制备和使用方法 | |
CN104888235A (zh) | 具有共递送多个药物的pH敏感纳米粒前药及其制备方法与应用 | |
EP3119395B1 (en) | Polymeric nanoparticles and methods of making and using same | |
CN105362223B (zh) | 一种可靶向药物的三嵌段共聚物胶束的制备方法 | |
Rodríguez-Acosta et al. | Polymer-dendrimer hybrids as carriers of anticancer agents | |
US20230414602A1 (en) | Pharmaceutical composition comprising insoluble camptothecin compound-containing nanoparticle for treatment of cancer and combination therapy thereof | |
TWI453034B (zh) | 用於治療腫瘤的醫藥組成物及其使用 | |
CN105688225A (zh) | 一种生物降解高分子-多西紫杉醇键合药及其制备方法 | |
US20240131170A1 (en) | Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids | |
US20220184219A1 (en) | Method of Making Prodrug for Sustained and Controlled Release | |
US20150140109A1 (en) | Docetaxel-based prolonged-release cancer treatment drug | |
Shi et al. | Reduction-responsive and tumor-targeted polyprodrug nanocarriers for targeting therapy of hepatocellular carcinoma | |
Yue | Synthesis And Application of Partial Block Polymers in Drug Delivery | |
JP2013535443A (ja) | 5−フルオロ−2−[[(1s)−1−(5−フルオロ−2−ピリジル)エチル]アミノ]−6−[(5−イソプロポキシ−1h−ピラゾール−3−イル)アミノ]ピリジン−3−カルボニトリルのための医薬用デポ剤 | |
KR20140118458A (ko) | Sda/pei 공중합체 및 이를 포함하는 유전자 전달체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09843559 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2759060 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009843559 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13265802 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0924951 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0924951 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111021 |